Avient (AVNT) investor relations material

Executive summary

• Full-year 2025 sales reached $3,260M, up 0.6% as reported, with adjusted EBITDA of $545M, up 3.5%, and adjusted EPS of $2.82, up 6% year-over-year, driven by innovation, productivity, and strong performance in defense, healthcare, and telecom.

• Q4 2025 sales were $761M, up 1.9% as reported, with adjusted EBITDA of $118M, up 7.4%, and adjusted EPS of $0.56, up 14% year-over-year.

• Record-high adjusted EBITDA margin of 16.7% for 2025, with margin expansion in all four quarters.

• No acquisitions or divestitures in the past two years, providing clean financial comparisons and highlighting organic growth.

• Strong free cash flow of $195M enabled $150M in debt repayment, reducing net leverage to 2.6x.

Financial highlights

• Adjusted EBITDA margin expanded by 50 bps to 16.7% for FY 2025 and by 80 bps to 15.5% in Q4 2025.

• Adjusted EPS up 6% year-over-year; free cash flow of $195M enabled $150M debt reduction.

• Net leverage improved from 3.1x in 2023 to 2.6x in 2025.

• Adjusted ROIC increased to 8.6% in 2025 from 8.3% in 2024, up 90 bps since 2023.

• Adjusted operating income for 2025 was $362.8M, up from $350.7M in 2024.

Outlook and guidance

• 2026 adjusted EBITDA guidance: $555M–$585M (up 2%–7% YoY); adjusted EPS: $2.93–$3.17 (up 4%–12%).

• Q1 2026 adjusted EPS outlook: $0.81, up 7% year-over-year.

• Free cash flow for 2026 expected at $200M–$220M, with $140M in capex, mainly for defense capacity expansion.

• Macro assumptions include easing interest rates, government policy support, and continued NATO defense spending, but persistent inflation and FX volatility remain risks.

• Cautiously optimistic for 2026, expecting modest growth in consumer, industrial, and construction markets, with packaging and healthcare remaining strong.